(Date:3/12/2010)... is taking strides to expand their Product and Material Testing Division ... ... Minneapolis, MN (PRWEB) March 12, 2010 -- DDL , leader ... to expand their Product and Material Testing Division by promoting Mark ... medical device manufacturers get to market for almost 20 years. ...
(Date:3/11/2010)... Drug Administration (FDA) has approved a five-day dosing regimen for Dacogen® (decitabine) for Injection to treat patients with myelodysplastic syndromes (MDS), a group of bone ... ... , ... ... ...
(Date:3/11/2010)... has signed a definitive agreement with Elan Pharmaceuticals, Inc. (a subsidiary of Elan Corporation, plc) ( ELN) ("Elan") to acquire the analgesic therapy, PRIALT(R) (ziconotide ... ... ... ... ...
(Date:3/11/2010)... a biopharmaceutical company developing innovative immune-based biologics, today announced that it has entered ... for Sick Children (SickKids) in Toronto, Ontario , granting Trillium exclusive worldwide ... transplantation and cancer. , ... ... , ...
Breaking Biology Technology:DDL Expands the Product & Material Testing Division 2DDL Expands the Product & Material Testing Division 3FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 2FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 3FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 4FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 5FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 6FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 7FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 8Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 2Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 3Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 4Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 5Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 6Trillium expands immunology pipeline and enters stem cell field through in-licensing of two new programs 2Trillium expands immunology pipeline and enters stem cell field through in-licensing of two new programs 3... 7, 2008 Light Sciences Oncology,Inc. (LSO) today announced ... Directors. The appointment increases Board membership to eight., ... a Director,of Endo Pharmaceuticals. He is the former President ... of Corporate Development with,Johnson & Johnson (NYSE: JNJ ...
... payments for achieving milestones ... ... TSX symbol: SBS, CALGARY, April 7 /PRNewswire-FirstCall/ - SemBioSys Genetics ... and cardiovascular diseases, today announced that it,has received milestone payments totaling ...
... Dr. David S. Young awarded "Most Innovative" award by the ... ... - ARIUS Research Inc. (TSX:,ARI), a biotechnology company discovering and ... David S. Young, President,and Chief Executive Officer, received the "Most ...
Other Biology Technology:Light Sciences Oncology Appoints David P. Holveck to Its Board of Directors 2SemBioSys receives milestone payments from AVAC Ltd. 2SemBioSys receives milestone payments from AVAC Ltd. 3SemBioSys receives milestone payments from AVAC Ltd. 4ARIUS recognized for entrepreneurial excellence 2